Winston & Strawn Represents Estrella Immunopharma in US$100 Million Shelf Registration

Winston & Strawn LLP represented Estrella Immunopharma, Inc., a Nasdaq-listed clinical-stage biopharmaceutical company focused on developing T-cell therapies, in connection with its effective Form S-3 registration statement filed with the Securities and Exchange Commission (SEC). The filing utilized a "shelf" registration process, allowing Estrella Immunopharma to offer and sell up to an aggregate of US$100 million of its common stock and warrants in one or more future primary offerings.